1-7 of 7
Thomas Bumm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical and Diagnostic Challenges in Patients with Concomitant Plasma Cell Disorders and Myeloproliferative Neoplasms

Maximilian J Steinhardt, Thomas Bumm, Xiang Zhou, Umair Munawar, Seungbin Han, Julia Mersi, Hermann Einsele, Leo Rasche, K. Martin Kortüm, Johannes M Waldschmidt
Journal: Blood
Blood (2023) 142 (Supplement 1): 6771.
https://doi.org/10.1182/blood-2023-189528
Published: 2023
Journal Articles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Brief Report
Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Peter Nollau, Thomas Bumm, Sebastian Böttcher, Ralf C. Bargou, Mascha Binder
Journal: Blood
Blood (2017) 129 (1): 100–104.
https://doi.org/10.1182/blood-2016-05-718395
Published: 2017
Includes: Supplemental data
Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger
Journal: Blood
Blood (2010) 116 (17): 3278–3285.
https://doi.org/10.1182/blood-2008-10-183665
Published: 2010
Includes: Supplemental data
Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2936.
https://doi.org/10.1182/blood.V110.11.2936.2936
Published: 2007
Journal Articles

Molecular Remission to Imatinib in Patients with Chronic Myeloid Leukaemia (CML) Is Less Durable Compared to Patients after Allografting.

Thoralf Lange, MD, Thomas Bumm, Marc Mueller, Sandra Otto, Haifa K. Al-Ali, MD, Leanthe Grommisch, MD, Scarlet Musiol, Christina Franke, Rainer Krahl, PHD, Dietger W. Niederwieser, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 276.
https://doi.org/10.1182/blood.V104.11.276.276
Published: 2004
Journal Articles

Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib.

Ian J. Griswold, PhD, Thomas Bumm, MD, Thomas O’Hare, PhD, Erika M. Moseson, Brian J. Druker, MD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 555.
https://doi.org/10.1182/blood.V104.11.555.555
Published: 2004
Journal Articles

Emergence of clonal cytogenetic abnormalities in Ph − cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

Thomas Bumm, Christel Müller, Haifa-Kathrin Al-Ali, Knut Krohn, Patricia Shepherd, Erika Schmidt, Sabine Leiblein, Christina Franke, Evelin Hennig, Thomas Friedrich, Reiner Krahl, Dietger Niederwieser, Michael W. N. Deininger
Journal: Blood
Blood (2003) 101 (5): 1941–1949.
https://doi.org/10.1182/blood-2002-07-2053
Published: 2003